ARK Genomic Revolution ETF (09KE)

Overview

The fund is a cutting-edge investment vehicle focusing on the burgeoning field of genomics, operating as an actively-managed exchange-traded fund (ETF). It seeks to capitalize on the transformative potential of genomics across various sectors, including healthcare, information technology, materials, energy, and consumer discretionary. By investing primarily in both domestic and foreign equity securities of companies at the forefront of the genomics revolution, the fund aims to offer investors unique exposure to this dynamic and rapidly evolving industry. Despite its concentrated theme, the fund maintains a broad perspective by integrating firms from multiple sectors that are instrumental in advancing genomics-related technologies and applications. It is non-diversified, indicating a focused investment strategy in companies specifically selected for their relevance to the genomics revolution.

Products and Services

• Equity Securities of Genomics Revolution Companies

  This product is the centerpiece of the fund's investment strategy, comprising a significant portion of its assets in domestic and foreign equity securities of companies leading the genomics revolution. By focusing on sectors such as healthcare, information technology, materials, energy, and consumer discretionary, the fund targets entities that are integral to the advancement of genomics. This includes firms engaged in genetic sequencing, gene editing, biotechnological innovation, and other areas that contribute to the evolution of genomics.